Janney Montgomery Scott LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 47.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 228,661 shares of the biopharmaceutical company's stock after selling 202,424 shares during the quarter. Janney Montgomery Scott LLC's holdings in Gilead Sciences were worth $21,121,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. State Street Corp lifted its stake in shares of Gilead Sciences by 1.4% in the 3rd quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company's stock valued at $5,044,795,000 after acquiring an additional 841,776 shares during the last quarter. Wellington Management Group LLP lifted its position in Gilead Sciences by 50.9% in the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company's stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the last quarter. FMR LLC boosted its stake in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company's stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Geode Capital Management LLC grew its holdings in shares of Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company's stock worth $2,302,119,000 after purchasing an additional 574,421 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Gilead Sciences by 3.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 7,752,975 shares of the biopharmaceutical company's stock worth $650,009,000 after buying an additional 224,960 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.
GILD has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. UBS Group raised their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Mizuho upped their price target on Gilead Sciences from $90.00 to $100.00 and gave the company an "outperform" rating in a research report on Thursday, November 21st. Morgan Stanley upgraded Gilead Sciences from an "equal weight" rating to an "overweight" rating and lifted their price objective for the stock from $87.00 to $113.00 in a research report on Friday, January 10th. Finally, Leerink Partners upgraded Gilead Sciences from a "market perform" rating to an "outperform" rating and upped their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $97.96.
View Our Latest Stock Analysis on Gilead Sciences
Shares of GILD opened at $93.07 on Friday. The firm has a market cap of $115.99 billion, a PE ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a fifty day simple moving average of $91.74 and a two-hundred day simple moving average of $84.86.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 earnings per share. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. Gilead Sciences's dividend payout ratio is currently 3,422.22%.
In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 6,788 shares of the business's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 456,234 shares of company stock worth $42,130,461. Company insiders own 0.16% of the company's stock.
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.